{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:51:20Z","timestamp":1793317880414,"version":"4.5.0"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271667"],"award-info":[{"award-number":["82271667"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02124-8","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:07:16Z","timestamp":1779779236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The central role of hyperandrogenism in driving metabolic dysfunction in polycystic ovary syndrome: from pathophysiological mechanisms to targeted therapies"],"prefix":"10.1186","volume":"19","author":[{"given":"Jinghui","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"2124_CR1","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1093\/humrep\/dew218","volume":"31","author":"G Bozdag","year":"2016","unstructured":"Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31:2841\u201355. https:\/\/doi.org\/10.1093\/humrep\/dew218.","journal-title":"Hum Reprod"},{"key":"2124_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4103\/jhrs.JHRS_95_18","volume":"13","author":"R Deswal","year":"2020","unstructured":"Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13:261\u201371. https:\/\/doi.org\/10.4103\/jhrs.JHRS_95_18.","journal-title":"J Hum Reprod Sci"},{"key":"2124_CR3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/biomedicines10030540","volume":"10","author":"H Nautiyal","year":"2022","unstructured":"Nautiyal H, Imam SS, Alshehri S, Ghoneim MM, Afzal M, Alzarea SI, et al. Polycystic ovarian syndrome: a complex disease with a genetics approach. Biomedicines. 2022;10:540. https:\/\/doi.org\/10.3390\/biomedicines10030540.","journal-title":"Biomedicines"},{"key":"2124_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/humrep\/deac001","volume":"37","author":"U Ezeh","year":"2022","unstructured":"Ezeh U, Pisarska MD, Azziz R. Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome. Hum Reprod. 2022;37:553\u201364. https:\/\/doi.org\/10.1093\/humrep\/deac001.","journal-title":"Hum Reprod"},{"key":"2124_CR5","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1097\/AOG.0000000000000852","volume":"125","author":"DA Doherty","year":"2015","unstructured":"Doherty DA, Newnham JP, Bower C, Hart R. Implications of polycystic ovary syndrome for pregnancy and for the health of offspring. Obstet Gynecol. 2015;125:1397\u2013406. https:\/\/doi.org\/10.1097\/AOG.0000000000000852.","journal-title":"Obstet Gynecol"},{"key":"2124_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1210\/er.2015-1018","volume":"36","author":"DA Dumesic","year":"2015","unstructured":"Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015;36:487\u2013525. https:\/\/doi.org\/10.1210\/er.2015-1018.","journal-title":"Endocr Rev"},{"key":"2124_CR7","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.3390\/cells11203255","volume":"11","author":"E Carmina","year":"2022","unstructured":"Carmina E, Longo RA. Increased prevalence of elevated DHEAS in PCOS women with non-classic (B or C) phenotypes: a retrospective analysis in patients aged 20 to 29 years. Cells. 2022;11:3255. https:\/\/doi.org\/10.3390\/cells11203255.","journal-title":"Cells"},{"key":"2124_CR8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/humrep\/des463","volume":"28","author":"NK Stepto","year":"2013","unstructured":"Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013;28:777\u201384. https:\/\/doi.org\/10.1093\/humrep\/des463.","journal-title":"Hum Reprod"},{"key":"2124_CR9","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/jcmm.16205","volume":"25","author":"W Ye","year":"2021","unstructured":"Ye W, Xie T, Song Y, Zhou L. The role of androgen and its related signals in PCOS. J Cell Mol Med. 2021;25:1825\u201337. https:\/\/doi.org\/10.1111\/jcmm.16205.","journal-title":"J Cell Mol Med"},{"key":"2124_CR10","doi-asserted-by":"publisher","first-page":"155164","DOI":"10.1016\/j.metabol.2022.155164","volume":"131","author":"H Shen","year":"2022","unstructured":"Shen H, Xu X, Fu Z, Xu C, Wang Y. The interactions of CAP and LYN with the insulin signaling transducer CBL play an important role in polycystic ovary syndrome. Metabolism. 2022;131:155164. https:\/\/doi.org\/10.1016\/j.metabol.2022.155164.","journal-title":"Metabolism"},{"key":"2124_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.fertnstert.2022.03.009","volume":"117","author":"C Guan","year":"2022","unstructured":"Guan C, Zahid S, Minhas AS, Ouyang P, Vaught A, Baker VL, et al. Polycystic ovary syndrome: a \u201crisk-enhancing\u201d factor for cardiovascular disease. Fertil Steril. 2022;117:924\u201335. https:\/\/doi.org\/10.1016\/j.fertnstert.2022.03.009.","journal-title":"Fertil Steril"},{"key":"2124_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jgh3.12512","volume":"5","author":"M Shengir","year":"2021","unstructured":"Shengir M, Chen T, Guadagno E, Ramanakumar AV, Ghali P, Deschenes M, et al. Non-alcoholic fatty liver disease in premenopausal women with polycystic ovary syndrome: a systematic review and meta-analysis. JGH Open. 2021;5:434\u201345. https:\/\/doi.org\/10.1002\/jgh3.12512.","journal-title":"JGH Open"},{"key":"2124_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/humupd\/dmad015","volume":"29","author":"M Mill\u00e1n-de-Meer","year":"2023","unstructured":"Mill\u00e1n-de-Meer M, Luque-Ram\u00edrez M, Nattero-Ch\u00e1vez L, Escobar-Morreale HF. PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis. Hum Reprod Update. 2023;29:741\u201372. https:\/\/doi.org\/10.1093\/humupd\/dmad015.","journal-title":"Hum Reprod Update"},{"issue":"Suppl 4","key":"2124_CR14","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/s0015-0282(02)02985-0","volume":"77","author":"HG Burger","year":"2002","unstructured":"Burger HG. Androgen production in women. Fertil Steril. 2002;77(Suppl 4):S3-5. https:\/\/doi.org\/10.1016\/s0015-0282(02)02985-0.","journal-title":"Fertil Steril"},{"key":"2124_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jsbmb.2019.04.008","volume":"190","author":"BG Keevil","year":"2019","unstructured":"Keevil BG, Adaway J. Assessment of free testosterone concentration. J Steroid Biochem Mol Biol. 2019;190:207\u201311. https:\/\/doi.org\/10.1016\/j.jsbmb.2019.04.008.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2124_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1210\/er.2010-0013","volume":"32","author":"WL Miller","year":"2011","unstructured":"Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev. 2011;32:81\u2013151. https:\/\/doi.org\/10.1210\/er.2010-0013.","journal-title":"Endocr Rev"},{"key":"2124_CR17","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1093\/humrep\/deaf114","volume":"40","author":"F Tosi","year":"2025","unstructured":"Tosi F, Lando MG, Rosmini F, Lucarini F, Fiorio V, Zanolin ME, et al. Alterations of insulin sensitivity, clearance, and secretion, either alone or in combination, in women with PCOS: impact on metabolic profile and androgenemia. Hum Reprod. 2025;40:1550\u201361. https:\/\/doi.org\/10.1093\/humrep\/deaf114.","journal-title":"Hum Reprod"},{"key":"2124_CR18","doi-asserted-by":"publisher","first-page":"741764","DOI":"10.3389\/fendo.2021.741764","volume":"12","author":"H Ding","year":"2021","unstructured":"Ding H, Zhang J, Zhang F, Zhang S, Chen X, Liang W, et al. Resistance to the insulin and elevated level of androgen: a major cause of polycystic ovary syndrome. Front Endocrinol (Lausanne). 2021;12:741764. https:\/\/doi.org\/10.3389\/fendo.2021.741764.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2124_CR19","doi-asserted-by":"publisher","first-page":"116940","DOI":"10.1016\/j.lfs.2019.116940","volume":"236","author":"J Wang","year":"2019","unstructured":"Wang J, Wu D, Guo H, Li M. Hyperandrogenemia and insulin resistance: the chief culprit of polycystic ovary syndrome. Life Sci. 2019;236:116940. https:\/\/doi.org\/10.1016\/j.lfs.2019.116940.","journal-title":"Life Sci"},{"key":"2124_CR20","doi-asserted-by":"publisher","first-page":"110561","DOI":"10.1016\/j.mce.2019.110561","volume":"498","author":"C Coyle","year":"2019","unstructured":"Coyle C, Campbell RE. Pathological pulses in PCOS. Mol Cell Endocrinol. 2019;498:110561. https:\/\/doi.org\/10.1016\/j.mce.2019.110561.","journal-title":"Mol Cell Endocrinol"},{"key":"2124_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/cen.14704","volume":"97","author":"A Garg","year":"2022","unstructured":"Garg A, Patel B, Abbara A, Dhillo WS. Treatments targeting neuroendocrine dysfunction in polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf). 2022;97:156\u201364. https:\/\/doi.org\/10.1111\/cen.14704.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2124_CR22","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1007\/s11845-021-02733-w","volume":"191","author":"E Zarei","year":"2022","unstructured":"Zarei E, Binabaj MM, Zadeh FM, Bakhshandeh Nosrat S, Veghari G, Mansourian A. Kisspeptin levels in relation to sex hormone profile among PCOS patients. Ir J Med Sci. 2022;191:1711\u20136. https:\/\/doi.org\/10.1007\/s11845-021-02733-w.","journal-title":"Ir J Med Sci"},{"key":"2124_CR23","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.3390\/ijerph19053089","volume":"19","author":"A Szeliga","year":"2022","unstructured":"Szeliga A, Rudnicka E, Maciejewska-Jeske M, Kucharski M, Kostrzak A, Hajbos M, et al. Neuroendocrine determinants of polycystic ovary syndrome. Int J Environ Res Public Health. 2022;19:3089. https:\/\/doi.org\/10.3390\/ijerph19053089.","journal-title":"Int J Environ Res Public Health"},{"key":"2124_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3390\/medsci7080084","volume":"7","author":"EA Coutinho","year":"2019","unstructured":"Coutinho EA, Kauffman AS. The role of the brain in the pathogenesis and physiology of polycystic ovary syndrome (PCOS). Med Sci (Basel). 2019;7:84. https:\/\/doi.org\/10.3390\/medsci7080084.","journal-title":"Med Sci (Basel)"},{"key":"2124_CR25","doi-asserted-by":"publisher","first-page":"104850","DOI":"10.1016\/j.ebiom.2023.104850","volume":"97","author":"MSB Silva","year":"2023","unstructured":"Silva MSB, Decoster L, Delpouve G, Lhomme T, Ternier G, Prevot V, et al. Overactivation of GnRH neurons is sufficient to trigger polycystic ovary syndrome-like traits in female mice. EBioMedicine. 2023;97:104850. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104850.","journal-title":"EBioMedicine"},{"key":"2124_CR26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","volume":"37","author":"RL Rosenfield","year":"2016","unstructured":"Rosenfield RL, Ehrmann DA. The pathogenesis of Polycystic Ovary Syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37:467\u2013520. https:\/\/doi.org\/10.1210\/er.2015-1104.","journal-title":"Endocr Rev"},{"key":"2124_CR27","doi-asserted-by":"publisher","first-page":"bnaa010","DOI":"10.1210\/endrev\/bnaa010","volume":"41","author":"E Stener-Victorin","year":"2020","unstructured":"Stener-Victorin E, Padmanabhan V, Walters KA, Campbell RE, Benrick A, Giacobini P, et al. Animal models to understand the etiology and pathophysiology of polycystic ovary syndrome. Endocr Rev. 2020;41:bnaa010. https:\/\/doi.org\/10.1210\/endrev\/bnaa010.","journal-title":"Endocr Rev"},{"key":"2124_CR28","doi-asserted-by":"publisher","first-page":"R98","DOI":"10.1093\/ejendo\/lvad047","volume":"188","author":"K-H Storbeck","year":"2023","unstructured":"Storbeck K-H, O\u2019Reilly MW. The clinical and biochemical significance of 11-oxygenated androgens in human health and disease. Eur J Endocrinol. 2023;188:R98-109. https:\/\/doi.org\/10.1093\/ejendo\/lvad047.","journal-title":"Eur J Endocrinol"},{"key":"2124_CR29","doi-asserted-by":"publisher","first-page":"K47","DOI":"10.1530\/EJE-22-0518","volume":"187","author":"MK Auer","year":"2022","unstructured":"Auer MK, Hawley JM, Lottspeich C, Bidlingmaier M, Sappl A, Nowotny HF, et al. 11-Oxygenated androgens are not secreted by the human ovary: in-vivo data from four different cases of hyperandrogenism. Eur J Endocrinol. 2022;187:K47-53. https:\/\/doi.org\/10.1530\/EJE-22-0518.","journal-title":"Eur J Endocrinol"},{"key":"2124_CR30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cca.2019.11.003","volume":"502","author":"X Zeng","year":"2020","unstructured":"Zeng X, Xie Y-J, Liu Y-T, Long S-L, Mo Z-C. Polycystic ovarian syndrome: correlation between hyperandrogenism, insulin resistance and obesity. Clin Chim Acta. 2020;502:214\u201321. https:\/\/doi.org\/10.1016\/j.cca.2019.11.003.","journal-title":"Clin Chim Acta"},{"key":"2124_CR31","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1007\/s10787-025-01875-y","volume":"33","author":"A Siddiqua","year":"2025","unstructured":"Siddiqua A, Malik A, Iqbal U. Modulating endoplasmic reticulum stress and NLRP3 inflammasome in polycystic ovary syndrome: a review of natural and synthetic compounds. Inflammopharmacology. 2025;33:4519\u201333. https:\/\/doi.org\/10.1007\/s10787-025-01875-y.","journal-title":"Inflammopharmacology"},{"key":"2124_CR32","doi-asserted-by":"publisher","unstructured":"Rosenfield RL, Dumesic DA. On the Intimate relationship of adiposity to polycystic ovary syndrome. J Clin Endocrinol Metab. 2025;dgaf527. https:\/\/doi.org\/10.1210\/clinem\/dgaf527","DOI":"10.1210\/clinem\/dgaf527"},{"key":"2124_CR33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12020-023-03436-1","volume":"82","author":"K Stefanaki","year":"2023","unstructured":"Stefanaki K, Karagiannakis DS, Raftopoulou M, Psaltopoulou T, Paschou SA, Ilias I. Obesity and hyperandrogenism are implicated with anxiety, depression and food cravings in women with polycystic ovary syndrome. Endocrine. 2023;82:201\u20138. https:\/\/doi.org\/10.1007\/s12020-023-03436-1.","journal-title":"Endocrine"},{"key":"2124_CR34","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1210\/clinem\/dgae488","volume":"109","author":"M Amiri","year":"2024","unstructured":"Amiri M, Hatoum S, Hopkins D, Buyalos RP, Ezeh U, Pace LA, et al. The association between obesity and polycystic ovary syndrome: an epidemiologic study of observational data. J Clin Endocrinol Metab. 2024;109:2640\u201357. https:\/\/doi.org\/10.1210\/clinem\/dgae488.","journal-title":"J Clin Endocrinol Metab"},{"key":"2124_CR35","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ando.2022.11.004","volume":"84","author":"M Lemaitre","year":"2023","unstructured":"Lemaitre M, Christin-Maitre S, Kerlan V. Polycystic ovary syndrome and adipose tissue. Ann Endocrinol (Paris). 2023;84:308\u201315. https:\/\/doi.org\/10.1016\/j.ando.2022.11.004.","journal-title":"Ann Endocrinol (Paris)"},{"key":"2124_CR36","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000494902","volume":"53","author":"E Diamanti-Kandarakis","year":"2019","unstructured":"Diamanti-Kandarakis E, Papalou O, Kandaraki EA. The role of androgen excess on insulin sensitivity in women. Front Horm Res. 2019;53:50\u201364. https:\/\/doi.org\/10.1159\/000494902.","journal-title":"Front Horm Res"},{"key":"2124_CR37","doi-asserted-by":"publisher","first-page":"bvad079","DOI":"10.1210\/jendso\/bvad079","volume":"7","author":"DA Dumesic","year":"2023","unstructured":"Dumesic DA, Turcu AF, Liu H, Grogan TR, Abbott DH, Lu G, et al. Interplay of cortisol, testosterone, and abdominal fat mass in normal-weight women with polycystic ovary syndrome. J Endocr Soc. 2023;7:bvad079 (2023072014375910400).","journal-title":"J Endocr Soc"},{"key":"2124_CR38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/humupd\/dmab004","volume":"27","author":"SF de Medeiros","year":"2021","unstructured":"de Medeiros SF, Rodgers RJ, Norman RJ. Adipocyte and steroidogenic cell cross-talk in polycystic ovary syndrome. Hum Reprod Update. 2021;27:771\u201396. https:\/\/doi.org\/10.1093\/humupd\/dmab004.","journal-title":"Hum Reprod Update"},{"key":"2124_CR39","doi-asserted-by":"publisher","first-page":"112416","DOI":"10.1016\/j.mce.2024.112416","volume":"595","author":"G Levate","year":"2024","unstructured":"Levate G, Wang Y, McCredie R, Fenwick M, Rae MT, Duncan WC, et al. Insights into the effects of sex and tissue location on the evolution of adipocyte dysfunction in an ovine model of polycystic ovary syndrome (PCOS). Mol Cell Endocrinol. 2024;595:112416. https:\/\/doi.org\/10.1016\/j.mce.2024.112416.","journal-title":"Mol Cell Endocrinol"},{"key":"2124_CR40","doi-asserted-by":"publisher","first-page":"111137","DOI":"10.1016\/j.mce.2020.111137","volume":"523","author":"J Dou","year":"2021","unstructured":"Dou J, Puttabyatappa M, Padmanabhan V, Bakulski KM. Developmental programming: adipose depot-specific transcriptional regulation by prenatal testosterone excess in a sheep model of PCOS. Mol Cell Endocrinol. 2021;523:111137. https:\/\/doi.org\/10.1016\/j.mce.2020.111137.","journal-title":"Mol Cell Endocrinol"},{"key":"2124_CR41","doi-asserted-by":"publisher","unstructured":"Dumesic DA, Phan JD, Leung KL, Grogan TR, Ding X, Li X, et al. Adipose Insulin Resistance in Normal-Weight Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2019;104:2171\u201383. https:\/\/doi.org\/10.1210\/jc.2018-02086.","DOI":"10.1210\/jc.2018-02086"},{"key":"2124_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/cen.13913","volume":"90","author":"S Shorakae","year":"2019","unstructured":"Shorakae S, Jona E, de Courten B, Lambert GW, Lambert EA, Phillips SE, et al. Brown adipose tissue thermogenesis in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2019;90:425\u201332. https:\/\/doi.org\/10.1111\/cen.13913.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2124_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03590-6","author":"D Wang","year":"2023","unstructured":"Wang D, Zhao H, Xing C, Lv B, Wang X, He B. Androgens exacerbate hepatic triglyceride accumulation in rats with polycystic ovary syndrome by downregulating MTTP expression. Endocrine. 2023. https:\/\/doi.org\/10.1007\/s12020-023-03590-6.","journal-title":"Endocrine"},{"key":"2124_CR44","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/biomedicines10061291","volume":"10","author":"KJ Siemienowicz","year":"2022","unstructured":"Siemienowicz KJ, Filis P, Thomas J, Fowler PA, Duncan WC, Rae MT. Hepatic mitochondrial dysfunction and risk of liver disease in an ovine model of \u201cPCOS males.\u201d Biomedicines. 2022;10:1291. https:\/\/doi.org\/10.3390\/biomedicines10061291.","journal-title":"Biomedicines"},{"key":"2124_CR45","doi-asserted-by":"publisher","first-page":"105752","DOI":"10.1016\/j.jsbmb.2020.105752","volume":"204","author":"T Li","year":"2020","unstructured":"Li T, Zhang T, Cui T, Yang Y, Liu R, Chen Y, et al. Involvement of endogenous testosterone in hepatic steatosis in women with polycystic ovarian syndrome. J Steroid Biochem Mol Biol. 2020;204:105752. https:\/\/doi.org\/10.1016\/j.jsbmb.2020.105752.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2124_CR46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/biomedicines10010131","volume":"10","author":"S Spremovi\u0107 Ra\u0111enovi\u0107","year":"2022","unstructured":"Spremovi\u0107 Ra\u0111enovi\u0107 S, Pupovac M, Andji\u0107 M, Bila J, Sre\u0107kovi\u0107 S, Gudovi\u0107 A, et al. Prevalence, risk factors, and pathophysiology of nonalcoholic fatty liver disease (NAFLD) in women with polycystic ovary syndrome (PCOS). Biomedicines. 2022;10:131. https:\/\/doi.org\/10.3390\/biomedicines10010131.","journal-title":"Biomedicines"},{"key":"2124_CR47","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024;73:691\u2013702. https:\/\/doi.org\/10.1136\/gutjnl-2023-330595.","journal-title":"Gut"},{"key":"2124_CR48","doi-asserted-by":"publisher","first-page":"e000352","DOI":"10.1136\/bmjgast-2019-000352","volume":"7","author":"MM Asfari","year":"2020","unstructured":"Asfari MM, Sarmini MT, Baidoun F, Al-Khadra Y, Ezzaizi Y, Dasarathy S, et al. Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome. BMJ Open Gastroenterol. 2020;7:e000352. https:\/\/doi.org\/10.1136\/bmjgast-2019-000352.","journal-title":"BMJ Open Gastroenterol"},{"key":"2124_CR49","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.dsx.2018.12.020","volume":"13","author":"S Harsha Varma","year":"2019","unstructured":"Harsha Varma S, Tirupati S, Pradeep TVS, Sarathi V, Kumar D. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Diabetes Metab Syndr Clin Res Rev. 2019;13:1065\u20139. https:\/\/doi.org\/10.1016\/j.dsx.2018.12.020.","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"2124_CR50","doi-asserted-by":"publisher","first-page":"13397","DOI":"10.1038\/s41598-023-39428-4","volume":"13","author":"S-H Hong","year":"2023","unstructured":"Hong S-H, Sung Y-A, Hong YS, Song DK, Jung H, Jeong K, et al. Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome. Sci Rep. 2023;13:13397. https:\/\/doi.org\/10.1038\/s41598-023-39428-4.","journal-title":"Sci Rep"},{"key":"2124_CR51","doi-asserted-by":"publisher","first-page":"1480528","DOI":"10.3389\/fendo.2025.1480528","volume":"16","author":"S-H Hong","year":"2025","unstructured":"Hong S-H, Sung Y-A, Hong YS, Song DK, Jung H, Jeong K, et al. The association between phenotypes of polycystic ovary syndrome and metabolic dysfunction-associated fatty liver disease. Front Endocrinol (Lausanne). 2025;16:1480528. https:\/\/doi.org\/10.3389\/fendo.2025.1480528.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2124_CR52","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1210\/clinem\/dgae481","volume":"110","author":"AE Henney","year":"2025","unstructured":"Henney AE, Gillespiec CS, Lai JYM, Schofield P, Riley DR, Caleyachetty R, et al. Risk of type 2 diabetes, MASLD and cardiovascular disease in people living with polycystic ovary syndrome. J Clin Endocrinol Metab. 2025;110:1235\u201346. https:\/\/doi.org\/10.1210\/clinem\/dgae481.","journal-title":"J Clin Endocrinol Metab"},{"key":"2124_CR53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5603\/ep.101924","volume":"76","author":"D Pluta","year":"2025","unstructured":"Pluta D, Migacz M, Kochman K, Krajewski B, Holecki M, Madej P. Polycystic ovary syndrome patients with metabolic dysfunction-associated steatotic liver disease - comparison of the diagnostic methods. Endokrynol Pol. 2025;76:145\u201352. https:\/\/doi.org\/10.5603\/ep.101924.","journal-title":"Endokrynol Pol"},{"key":"2124_CR54","doi-asserted-by":"publisher","unstructured":"Roy S, Abudu A, Salinas I, Sinha N, Cline-Fedewa H, Yaw AM, et al. Androgen-mediated Perturbation of the Hepatic Circadian System Through Epigenetic Modulation Promotes NAFLD in PCOS Mice. Endocrinology. 2022;163:bqac127. https:\/\/doi.org\/10.1210\/endocr\/bqac127.","DOI":"10.1210\/endocr\/bqac127"},{"key":"2124_CR55","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/jcm12020557","volume":"12","author":"A Giannouli","year":"2023","unstructured":"Giannouli A, Efthymiou V, Konidari M, Mani I, Aravantinos L, Dourakis SP, et al. The burden of non-alcoholic fatty liver disease in adolescents with polycystic ovary syndrome: a case-control study. J Clin Med Basel. 2023;12:557. https:\/\/doi.org\/10.3390\/jcm12020557.","journal-title":"J Clin Med Basel"},{"key":"2124_CR56","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.fertnstert.2023.07.025","volume":"120","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2023;120:767\u201393. https:\/\/doi.org\/10.1016\/j.fertnstert.2023.07.025.","journal-title":"Fertil Steril"},{"key":"2124_CR57","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/joim.20103","volume":"298","author":"W Balkhed","year":"2025","unstructured":"Balkhed W, Bergram M, Iredahl F, Holmberg M, Edin C, Carlh\u00e4ll C-J, et al. Evaluating the prevalence and severity of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus in primary care. J Intern Med. 2025;298:173\u201387. https:\/\/doi.org\/10.1111\/joim.20103.","journal-title":"J Intern Med"},{"key":"2124_CR58","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.14309\/ajg.0000000000003268","volume":"120","author":"WR Kim","year":"2025","unstructured":"Kim WR, Mannalithara A, Charu V, Chung N, Kwong A, Kwo PY, et al. Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease. Am J Gastroenterol. 2025;120:2312\u201320. https:\/\/doi.org\/10.14309\/ajg.0000000000003268.","journal-title":"Am J Gastroenterol"},{"key":"2124_CR59","doi-asserted-by":"publisher","first-page":"109306","DOI":"10.1016\/j.steroids.2023.109306","volume":"199","author":"J Rizk","year":"2023","unstructured":"Rizk J, Sahu R, Duteil D. An overview on androgen-mediated actions in skeletal muscle and adipose tissue. Steroids. 2023;199:109306. https:\/\/doi.org\/10.1016\/j.steroids.2023.109306.","journal-title":"Steroids"},{"key":"2124_CR60","doi-asserted-by":"publisher","first-page":"e2407768121","DOI":"10.1073\/pnas.2407768121","volume":"121","author":"H Sakai","year":"2024","unstructured":"Sakai H, Uno H, Yamakawa H, Tanaka K, Ikedo A, Uezumi A, et al. The androgen receptor in mesenchymal progenitors regulates skeletal muscle mass via Igf1 expression in male mice. Proc Natl Acad Sci U S A. 2024;121:e2407768121. https:\/\/doi.org\/10.1073\/pnas.2407768121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2124_CR61","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3109\/09513590.2014.982083","volume":"31","author":"GS Kogure","year":"2015","unstructured":"Kogure GS, Silva RC, Picchi Ramos FK, Miranda-Furtado CL, Lara LAdaS, Ferriani RA, et al. Women with polycystic ovary syndrome have greater muscle strength irrespective of body composition. Gynecol Endocrinol. 2015;31:237\u201342. https:\/\/doi.org\/10.3109\/09513590.2014.982083.","journal-title":"Gynecol Endocrinol"},{"key":"2124_CR62","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/dom.14206","volume":"23","author":"P Dandona","year":"2021","unstructured":"Dandona P, Dhindsa S, Ghanim H, Saad F. Mechanisms underlying the metabolic actions of testosterone in humans: a narrative review. Diabetes Obes Metab. 2021;23:18\u201328. https:\/\/doi.org\/10.1111\/dom.14206.","journal-title":"Diabetes Obes Metab"},{"key":"2124_CR63","doi-asserted-by":"publisher","first-page":"204201882211131","DOI":"10.1177\/20420188221113140","volume":"13","author":"T McDonnell","year":"2022","unstructured":"McDonnell T, Cussen L, McIlroy M, O\u2019Reilly MW. Characterizing skeletal muscle dysfunction in women with polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2022;13:20420188221113140. https:\/\/doi.org\/10.1177\/20420188221113140.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2124_CR64","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00404-019-05229-2","volume":"300","author":"E Caliskan Guzelce","year":"2019","unstructured":"Caliskan Guzelce E, Eyupoglu D, Torgutalp S, Aktoz F, Portakal O, Demirel H, et al. Is muscle mechanical function altered in polycystic ovary syndrome? Arch Gynecol Obstet. 2019;300:771\u20136. https:\/\/doi.org\/10.1007\/s00404-019-05229-2.","journal-title":"Arch Gynecol Obstet"},{"key":"2124_CR65","doi-asserted-by":"publisher","first-page":"7918","DOI":"10.3390\/ijms21217918","volume":"21","author":"A DeChick","year":"2020","unstructured":"DeChick A, Hetz R, Lee J, Speelman DL. Increased skeletal muscle fiber cross-sectional area, muscle phenotype shift, and altered insulin signaling in rat hindlimb muscles in a prenatally androgenized rat model for polycystic ovary syndrome. Int J Mol Sci. 2020;21:7918. https:\/\/doi.org\/10.3390\/ijms21217918.","journal-title":"Int J Mol Sci"},{"key":"2124_CR66","doi-asserted-by":"publisher","first-page":"RP87592","DOI":"10.7554\/eLife.87592","volume":"12","author":"E Stener-Victorin","year":"2024","unstructured":"Stener-Victorin E, Eriksson G, Mohan Shrestha M, Rodriguez Paris V, Lu H, Banks J, et al. Proteomic analysis shows decreased type I fibers and ectopic fat accumulation in skeletal muscle from women with PCOS. Elife. 2024;12:RP87592. https:\/\/doi.org\/10.7554\/eLife.87592.","journal-title":"Elife"},{"key":"2124_CR67","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1210\/jc.2018-01771","volume":"104","author":"SL Hansen","year":"2019","unstructured":"Hansen SL, Svendsen PF, Jeppesen JF, Hoeg LD, Andersen NR, Kristensen JM, et al. Molecular mechanisms in skeletal muscle underlying insulin resistance in women who are lean with polycystic ovary syndrome. J Clin Endocrinol Metab. 2019;104:1841\u201354. https:\/\/doi.org\/10.1210\/jc.2018-01771.","journal-title":"J Clin Endocrinol Metab"},{"key":"2124_CR68","doi-asserted-by":"publisher","first-page":"e13255","DOI":"10.1111\/obr.13255","volume":"22","author":"M Kazemi","year":"2021","unstructured":"Kazemi M, Pierson RA, Parry SA, Kaviani M, Chilibeck PD. Obesity, but not hyperandrogenism or insulin resistance, predicts skeletal muscle mass in reproductive-aged women with polycystic ovary syndrome: a systematic review and meta-analysis of 45 observational studies. Obes Rev. 2021;22:e13255. https:\/\/doi.org\/10.1111\/obr.13255.","journal-title":"Obes Rev"},{"key":"2124_CR69","doi-asserted-by":"publisher","first-page":"112529","DOI":"10.1016\/j.celrep.2023.112529","volume":"42","author":"W Xu","year":"2023","unstructured":"Xu W, Qadir MMF, Nasteska D, Mota de Sa P, Gorvin CM, Blandino-Rosano M, et al. Architecture of androgen receptor pathways amplifying glucagon-like peptide-1 insulinotropic action in male pancreatic \u03b2 cells. Cell Rep. 2023;42:112529. https:\/\/doi.org\/10.1016\/j.celrep.2023.112529.","journal-title":"Cell Rep"},{"key":"2124_CR70","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12967-023-04116-4","volume":"21","author":"S Shabbir","year":"2023","unstructured":"Shabbir S, Khurram E, Moorthi VS, Eissa YTH, Kamal MA, Butler AE. The interplay between androgens and the immune response in polycystic ovary syndrome. J Transl Med. 2023;21:259. https:\/\/doi.org\/10.1186\/s12967-023-04116-4.","journal-title":"J Transl Med"},{"key":"2124_CR71","doi-asserted-by":"publisher","first-page":"e2401772","DOI":"10.1002\/advs.202401772","volume":"11","author":"S Torstensson","year":"2024","unstructured":"Torstensson S, Ascani A, Risal S, Lu H, Zhao A, Espinosa A, et al. Androgens modulate the immune profile in a mouse model of polycystic ovary syndrome. Adv Sci. 2024;11:e2401772. https:\/\/doi.org\/10.1002\/advs.202401772.","journal-title":"Adv Sci"},{"key":"2124_CR72","doi-asserted-by":"publisher","unstructured":"Whitton K, Baber R. Androgen-based therapies in women. Best Pract Res Cl En. 2023;101783. https:\/\/doi.org\/10.1016\/j.beem.2023.101783","DOI":"10.1016\/j.beem.2023.101783"},{"key":"2124_CR73","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s11883-023-01168-1","volume":"25","author":"YR Alvarez","year":"2023","unstructured":"Alvarez YR, Pico M, Ashokprabhu N, Abou-Amro K, Bailey S, Pung E, et al. Polycystic ovarian syndrome: a risk factor for cardiovascular disease. Curr Atheroscler Rep. 2023;25:1003\u201311. https:\/\/doi.org\/10.1007\/s11883-023-01168-1.","journal-title":"Curr Atheroscler Rep"},{"key":"2124_CR74","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13293-024-00586-3","volume":"15","author":"AC Horton","year":"2024","unstructured":"Horton AC, Wilkinson MM, Kilanowski-Doroh I, Dong Z, Liu J, Ogola BO, et al. Dihydrotestosterone induces arterial stiffening in female mice. Biol Sex Differ. 2024;15:9. https:\/\/doi.org\/10.1186\/s13293-024-00586-3.","journal-title":"Biol Sex Differ"},{"key":"2124_CR75","doi-asserted-by":"publisher","first-page":"16577","DOI":"10.3390\/ijms242316577","volume":"24","author":"A S\u00fcli","year":"2023","unstructured":"S\u00fcli A, Magyar P, Vez\u00e9r M, B\u00e1nyai B, Szekeres M, Sipos M, et al. Effects of gender and Vitamin D on vascular reactivity of the carotid artery on a testosterone-induced PCOS model. Int J Mol Sci. 2023;24:16577. https:\/\/doi.org\/10.3390\/ijms242316577.","journal-title":"Int J Mol Sci"},{"key":"2124_CR76","doi-asserted-by":"publisher","first-page":"8862878","DOI":"10.1155\/2021\/8862878","volume":"2021","author":"J Joksimovic Jovic","year":"2021","unstructured":"Joksimovic Jovic J, Sretenovic J, Jovic N, Rudic J, Zivkovic V, Srejovic I, et al. Cardiovascular properties of the androgen-induced PCOS model in rats: the role of oxidative stress. Oxid Med Cell Longev. 2021;2021:8862878. https:\/\/doi.org\/10.1155\/2021\/8862878.","journal-title":"Oxid Med Cell Longev"},{"key":"2124_CR77","doi-asserted-by":"publisher","first-page":"466","DOI":"10.4183\/aeb.2022.466","volume":"18","author":"HY Ya\u015far","year":"2022","unstructured":"Ya\u015far HY, Colak A, Demirpence M, Girgin E, Aslan FD, Taylan A, et al. Do androgens predict cardiovascular risk including cardiotrophin-1 levels in patients with obese and lean polycystic ovary syndrome. Acta Endocrinol (Buchar). 2022;18:466\u201373. https:\/\/doi.org\/10.4183\/aeb.2022.466.","journal-title":"Acta Endocrinol (Buchar)"},{"key":"2124_CR78","doi-asserted-by":"publisher","first-page":"e0236023","DOI":"10.1128\/spectrum.02360-23","volume":"11","author":"K Chen","year":"2023","unstructured":"Chen K, Geng H, Liu J, Ye C. Alteration in gut mycobiota of patients with polycystic ovary syndrome. Microbiol Spectr. 2023;11:e0236023. https:\/\/doi.org\/10.1128\/spectrum.02360-23.","journal-title":"Microbiol Spectr"},{"key":"2124_CR79","doi-asserted-by":"publisher","first-page":"1384233","DOI":"10.3389\/fcell.2024.1384233","volume":"12","author":"M Li","year":"2024","unstructured":"Li M, Chang Q, Luo Y, Pan J, Hu Y, Liu B, et al. The gut microbial composition in polycystic ovary syndrome with hyperandrogenemia and its association with steroid hormones. Front Cell Dev Biol. 2024;12:1384233. https:\/\/doi.org\/10.3389\/fcell.2024.1384233.","journal-title":"Front Cell Dev Biol"},{"key":"2124_CR80","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/life13010007","volume":"13","author":"L Suturina","year":"2022","unstructured":"Suturina L, Belkova N, Igumnov I, Lazareva L, Danusevich I, Nadeliaeva I, et al. Polycystic ovary syndrome and gut microbiota: phenotype matters. Life (Basel). 2022;13:7. https:\/\/doi.org\/10.3390\/life13010007.","journal-title":"Life (Basel)"},{"key":"2124_CR81","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40168-021-01046-5","volume":"9","author":"Q Han","year":"2021","unstructured":"Han Q, Wang J, Li W, Chen Z-J, Du Y. Androgen-induced gut dysbiosis disrupts glucolipid metabolism and endocrinal functions in polycystic ovary syndrome. Microbiome. 2021;9:101. https:\/\/doi.org\/10.1186\/s40168-021-01046-5.","journal-title":"Microbiome"},{"key":"2124_CR82","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.clnu.2024.10.028","volume":"43","author":"R Gautam","year":"2024","unstructured":"Gautam R, Maan P, Patel AK, Vasudevan S, Arora T. Unveiling the complex interplay between gut microbiota and polycystic ovary syndrome: a narrative review. Clin Nutr. 2024;43:199\u2013208. https:\/\/doi.org\/10.1016\/j.clnu.2024.10.028.","journal-title":"Clin Nutr"},{"key":"2124_CR83","doi-asserted-by":"publisher","first-page":"1142041","DOI":"10.3389\/fcimb.2023.1142041","volume":"13","author":"Y Sun","year":"2023","unstructured":"Sun Y, Gao S, Ye C, Zhao W. Gut microbiota dysbiosis in polycystic ovary syndrome: mechanisms of progression and clinical applications. Front Cell Infect Microbiol. 2023;13:1142041. https:\/\/doi.org\/10.3389\/fcimb.2023.1142041.","journal-title":"Front Cell Infect Microbiol"},{"key":"2124_CR84","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.3390\/cells12141888","volume":"12","author":"L Shi","year":"2023","unstructured":"Shi L, Jin L, Huang W. Bile acids, intestinal barrier dysfunction, and related diseases. Cells. 2023;12:1888. https:\/\/doi.org\/10.3390\/cells12141888.","journal-title":"Cells"},{"key":"2124_CR85","doi-asserted-by":"publisher","first-page":"139962","DOI":"10.1016\/j.ijbiomac.2025.139962","volume":"298","author":"T Nagano","year":"2025","unstructured":"Nagano T, Higashimura Y, Nakano M, Nishiuchi T, Lelo AP. High-viscosity dietary fibers modulate gut microbiota and liver metabolism to prevent obesity in high-fat diet-fed mice. Int J Biol Macromol. 2025;298:139962. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.139962.","journal-title":"Int J Biol Macromol"},{"key":"2124_CR86","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.metabol.2018.11.002","volume":"92","author":"CJ Glueck","year":"2019","unstructured":"Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics. Metabolism. 2019;92:108\u201320. https:\/\/doi.org\/10.1016\/j.metabol.2018.11.002.","journal-title":"Metabolism"},{"key":"2124_CR87","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.pathophys.2019.08.003","volume":"26","author":"OT Olaniyan","year":"2019","unstructured":"Olaniyan OT, Femi A, Iliya G, Ayobami D, Godam E, Olugbenga E, et al. Vitamin C suppresses ovarian pathophysiology in experimental polycystic ovarian syndrome. Pathophysiology. 2019;26:331\u201341. https:\/\/doi.org\/10.1016\/j.pathophys.2019.08.003.","journal-title":"Pathophysiology"},{"key":"2124_CR88","doi-asserted-by":"publisher","first-page":"121224","DOI":"10.1016\/j.lfs.2022.121224","volume":"313","author":"Y-C Wang","year":"2023","unstructured":"Wang Y-C, Ma Y-D, Liu H, Cui Z-H, Zhao D, Zhang X-Q, et al. Hyperandrogen-induced polyol pathway flux increase affects ovarian function in polycystic ovary syndrome via excessive oxidative stress. Life Sci. 2023;313:121224. https:\/\/doi.org\/10.1016\/j.lfs.2022.121224.","journal-title":"Life Sci"},{"key":"2124_CR89","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.2174\/0929867325666171205144119","volume":"25","author":"SR Ferreira","year":"2018","unstructured":"Ferreira SR, Motta AB. Uterine function: from normal to polycystic ovarian syndrome alterations. Curr Med Chem. 2018;25:1792\u2013804. https:\/\/doi.org\/10.2174\/0929867325666171205144119.","journal-title":"Curr Med Chem"},{"key":"2124_CR90","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.mce.2017.09.022","volume":"465","author":"I Simitsidellis","year":"2018","unstructured":"Simitsidellis I, Saunders PTK, Gibson DA. Androgens and endometrium: new insights and new targets. Mol Cell Endocrinol. 2018;465:48\u201360. https:\/\/doi.org\/10.1016\/j.mce.2017.09.022.","journal-title":"Mol Cell Endocrinol"},{"key":"2124_CR91","doi-asserted-by":"publisher","first-page":"788772","DOI":"10.3389\/fphys.2021.788772","volume":"12","author":"Z Xue","year":"2021","unstructured":"Xue Z, Li J, Feng J, Han H, Zhao J, Zhang J, et al. Research progress on the mechanism between polycystic ovary syndrome and abnormal endometrium. Front Physiol. 2021;12:788772. https:\/\/doi.org\/10.3389\/fphys.2021.788772.","journal-title":"Front Physiol"},{"key":"2124_CR92","doi-asserted-by":"publisher","unstructured":"Jiang S, Li H, Zhang L, Mu W, Zhang Y, Chen T, et al. Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 2024;gkae973. https:\/\/doi.org\/10.1093\/nar\/gkae973","DOI":"10.1093\/nar\/gkae973"},{"key":"2124_CR93","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.molmed.2023.02.006","volume":"29","author":"L Ib\u00e1\u00f1ez","year":"2023","unstructured":"Ib\u00e1\u00f1ez L, de Zegher F. Adolescent PCOS: a postpubertal central obesity syndrome. Trends Mol Med. 2023;29:354\u201363. https:\/\/doi.org\/10.1016\/j.molmed.2023.02.006.","journal-title":"Trends Mol Med"},{"key":"2124_CR94","doi-asserted-by":"publisher","first-page":"e2023064894","DOI":"10.1542\/peds.2023-064894","volume":"153","author":"RC Whooten","year":"2024","unstructured":"Whooten RC, Rifas-Shiman SL, Perng W, Chavarro JE, Taveras E, Oken E, et al. Associations of childhood adiposity and cardiometabolic biomarkers with adolescent PCOS. Pediatrics. 2024;153:e2023064894. https:\/\/doi.org\/10.1542\/peds.2023-064894.","journal-title":"Pediatrics"},{"key":"2124_CR95","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5603\/EP.a2019.0006","volume":"70","author":"A Dutkowska","year":"2019","unstructured":"Dutkowska A, Konieczna A, Breska-Kruszewska J, Sendrakowska M, Kowalska I, Racho\u0144 D. Recomendations on non-pharmacological interventions in women with PCOS to reduce body weight and improve metabolic disorders [Zalecenia dotycz\u0105ce post\u0119powania niefarmakologicznego u kobiet z PCOS celem zmniejszenia masy cia\u0142a i poprawy zaburze\u0144 metabolicznych]. Endokrynol Pol. 2019;70:198\u2013212. https:\/\/doi.org\/10.5603\/EP.a2019.0006.","journal-title":"Endokrynol Pol"},{"key":"2124_CR96","doi-asserted-by":"publisher","unstructured":"Shahid R, Iahtisham-Ul-Haq null, Mahnoor null, Awan KA, Iqbal MJ, Munir H, et al. Diet and lifestyle modifications for effective management of polycystic ovarian syndrome (PCOS). J Food Biochem. 2022;46:e14117. https:\/\/doi.org\/10.1111\/jfbc.14117","DOI":"10.1111\/jfbc.14117"},{"key":"2124_CR97","doi-asserted-by":"publisher","first-page":"735954","DOI":"10.3389\/fendo.2021.735954","volume":"12","author":"Y Shang","year":"2021","unstructured":"Shang Y, Zhou H, He R, Lu W. Dietary modification for reproductive health in women with polycystic ovary syndrome: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:735954. https:\/\/doi.org\/10.3389\/fendo.2021.735954.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2124_CR98","doi-asserted-by":"publisher","first-page":"112127","DOI":"10.1016\/j.nut.2023.112127","volume":"114","author":"R Wang","year":"2023","unstructured":"Wang R, Zhao Y, Fang X, Miao C, Ren N, Chen Y, et al. Effect of the ketogenic diet on gut microbiome composition and metabolomics in polycystic ovarian syndrome rats induced by letrozole and a high-fat diet. Nutrition. 2023;114:112127. https:\/\/doi.org\/10.1016\/j.nut.2023.112127.","journal-title":"Nutrition"},{"key":"2124_CR99","doi-asserted-by":"publisher","first-page":"12490","DOI":"10.3390\/ijerph182312490","volume":"18","author":"RI Cincione","year":"2021","unstructured":"Cincione RI, Losavio F, Ciolli F, Valenzano A, Cibelli G, Messina G, et al. Effects of mixed of a ketogenic diet in overweight and obese women with polycystic ovary syndrome. Int J Environ Res Public Health. 2021;18:12490. https:\/\/doi.org\/10.3390\/ijerph182312490.","journal-title":"Int J Environ Res Public Health"},{"key":"2124_CR100","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.1111\/dom.15801","volume":"26","author":"S Talebi","year":"2024","unstructured":"Talebi S, Shab-Bidar S, Moini A, Mohammadi H, Djafarian K. The effects of time-restricted eating alone or in combination with probiotic supplementation in comparison with a calorie-restricted diet on endocrine and metabolic profiles in women with polycystic ovary syndrome: a randomized clinical trial. Diabetes Obes Metab. 2024;26:4468\u201379. https:\/\/doi.org\/10.1111\/dom.15801.","journal-title":"Diabetes Obes Metab"},{"key":"2124_CR101","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jhep.2025.06.005","volume":"83","author":"JH Oh","year":"2025","unstructured":"Oh JH, Yoon EL, Park H, Lee S, Jo AJ, Cho S, et al. Efficacy and safety of time-restricted eating in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025;83:1256\u201365. https:\/\/doi.org\/10.1016\/j.jhep.2025.06.005.","journal-title":"J Hepatol"},{"key":"2124_CR102","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.clnu.2025.04.022","volume":"50","author":"H Akta\u015f","year":"2025","unstructured":"Akta\u015f H, Atakan MM, Aktitiz S, Erg\u00fcn Z, Ko\u015far \u015eN, Astorino TA, et al. Six weeks of time-restricted eating improves basal fat oxidation and body composition but not fat oxidation during exercise in young males. Clin Nutr. 2025;50:92\u2013103. https:\/\/doi.org\/10.1016\/j.clnu.2025.04.022.","journal-title":"Clin Nutr"},{"key":"2124_CR103","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/cen.14194","volume":"93","author":"VB Ribeiro","year":"2020","unstructured":"Ribeiro VB, Kogure GS, Lopes IP, Silva RC, Pedroso DCC, de Melo AS, et al. Effects of continuous and intermittent aerobic physical training on hormonal and metabolic profile, and body composition in women with polycystic ovary syndrome: a randomized controlled trial. Clin Endocrinol (Oxf). 2020;93:173\u201386. https:\/\/doi.org\/10.1111\/cen.14194.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2124_CR104","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/humupd\/dmae008","volume":"30","author":"D Ruiz-Gonz\u00e1lez","year":"2024","unstructured":"Ruiz-Gonz\u00e1lez D, Cavero-Redondo I, Hern\u00e1ndez-Mart\u00ednez A, Baena-Raya A, Mart\u00ednez-Forte S, Altm\u00e4e S, et al. Comparative efficacy of exercise, diet and\/or pharmacological interventions on BMI, ovulation, and hormonal profile in reproductive-aged women with overweight or obesity: a systematic review and network meta-analysis. Hum Reprod Update. 2024;30:472. https:\/\/doi.org\/10.1093\/humupd\/dmae008.","journal-title":"Hum Reprod Update"},{"key":"2124_CR105","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/humrep\/deac047","volume":"37","author":"RK Patten","year":"2022","unstructured":"Patten RK, McIlvenna LC, Levinger I, Garnham AP, Shorakae S, Parker AG, et al. High-intensity training elicits greater improvements in cardio-metabolic and reproductive outcomes than moderate-intensity training in women with polycystic ovary syndrome: a randomized clinical trial. Hum Reprod. 2022;37:1018\u201329. https:\/\/doi.org\/10.1093\/humrep\/deac047.","journal-title":"Hum Reprod"},{"key":"2124_CR106","doi-asserted-by":"publisher","first-page":"e47408","DOI":"10.7759\/cureus.47408","volume":"15","author":"SV Waghmare","year":"2023","unstructured":"Waghmare SV, Shanoo A. Polycystic Ovary Syndrome: a literature review with a focus on diagnosis, pathophysiology, and management. Cureus. 2023;15:e47408. https:\/\/doi.org\/10.7759\/cureus.47408.","journal-title":"Cureus"},{"key":"2124_CR107","doi-asserted-by":"publisher","first-page":"1223768","DOI":"10.3389\/fendo.2023.1223768","volume":"14","author":"H Zeng","year":"2023","unstructured":"Zeng H, Zhang Y, Huang S, Wu J, Ren W, Zhou L, et al. Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis. Front Endocrinol (Lausanne). 2023;14:1223768. https:\/\/doi.org\/10.3389\/fendo.2023.1223768.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2124_CR108","doi-asserted-by":"publisher","first-page":"E16","DOI":"10.1152\/ajpendo.00018.2018","volume":"316","author":"M Kupreeva","year":"2019","unstructured":"Kupreeva M, Diane A, Lehner R, Watts R, Ghosh M, Proctor S, et al. Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. Am J Physiol Endocrinol Metab. 2019;316:E16-33. https:\/\/doi.org\/10.1152\/ajpendo.00018.2018.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2124_CR109","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of Glucagon-like Peptide-1. Cell Metab. 2018;27:740\u201356. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001.","journal-title":"Cell Metab"},{"key":"2124_CR110","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s40265-022-01779-z","volume":"82","author":"S Yang","year":"2022","unstructured":"Yang S, Zhao L, He W, Mi Y. The effect of oral antidiabetic drugs on improving the endocrine and metabolic states in women with polycystic ovary syndrome: a systematic review and network meta-analysis. Drugs. 2022;82:1469\u201380. https:\/\/doi.org\/10.1007\/s40265-022-01779-z.","journal-title":"Drugs"},{"key":"2124_CR111","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s13679-025-00649-5","volume":"14","author":"S Yang","year":"2025","unstructured":"Yang S, Pan X, Yang R, Wang Y, Zhang Z, Chen G, et al. The efficacy of various weight loss strategies in alleviating polycystic ovary syndrome. Curr Obes Rep. 2025;14:57. https:\/\/doi.org\/10.1007\/s13679-025-00649-5.","journal-title":"Curr Obes Rep"},{"key":"2124_CR112","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/dom.16106","volume":"27","author":"Y Jiang","year":"2025","unstructured":"Jiang Y, Zhu H, Gong F. Why does GLP-1 agonist combined with GIP and\/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes? Diabetes Obes Metab. 2025;27:1079\u201395. https:\/\/doi.org\/10.1111\/dom.16106.","journal-title":"Diabetes Obes Metab"},{"key":"2124_CR113","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2337\/dci23-0100","volume":"47","author":"JC Locatelli","year":"2024","unstructured":"Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB, et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition? Diabetes Care. 2024;47:1718\u201330. https:\/\/doi.org\/10.2337\/dci23-0100.","journal-title":"Diabetes Care"},{"key":"2124_CR114","doi-asserted-by":"publisher","first-page":"106265","DOI":"10.1016\/j.jsbmb.2023.106265","volume":"229","author":"H Zhao","year":"2023","unstructured":"Zhao H, Wang D, Xing C, Lv B, Wang X, He B. Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear Factor-4\u03b1. J Steroid Biochem Mol Biol. 2023;229:106265. https:\/\/doi.org\/10.1016\/j.jsbmb.2023.106265.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2124_CR115","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.repbio.2020.05.004","volume":"20","author":"D Prabhu Y","year":"2020","unstructured":"Prabhu Y D, Gopalakrishnan A V. \u03b3-Linolenic acid ameliorates DHEA induced pro-inflammatory response in polycystic ovary syndrome via PPAR-\u03b3 signaling in rats. Reprod Biol. 2020;20:348\u201356. https:\/\/doi.org\/10.1016\/j.repbio.2020.05.004.","journal-title":"Reprod Biol"},{"key":"2124_CR116","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1111\/dom.14495","volume":"23","author":"S Tan","year":"2021","unstructured":"Tan S, Ignatenko S, Wagner F, Dokras A, Seufert J, Zwanziger D, et al. Licogliflozin versus placebo in women with Polycystic Ovary Syndrome: a randomized, double-blind, phase 2 trial. Diabetes Obes Metab. 2021;23:2595\u20139. https:\/\/doi.org\/10.1111\/dom.14495.","journal-title":"Diabetes Obes Metab"},{"key":"2124_CR117","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/IJWH.S344542","volume":"14","author":"C Xing","year":"2022","unstructured":"Xing C, Zhang J, Zhao H, He B. Effect of Sex Hormone-Binding Globulin on Polycystic Ovary Syndrome: mechanisms, manifestations, genetics, and treatment. Int J Womens Health. 2022;14:91\u2013105. https:\/\/doi.org\/10.2147\/IJWH.S344542. (New Zealand;).","journal-title":"Int J Womens Health"},{"key":"2124_CR118","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/cen.14913","volume":"99","author":"M Forslund","year":"2023","unstructured":"Forslund M, Melin J, Alesi S, Piltonen T, Romualdi D, Tay CT, et al. Combined oral contraceptive pill compared with no medical treatment in the management of polycystic ovary syndrome: a systematic review. Clin Endocrinol (Oxf). 2023;99:79\u201391. https:\/\/doi.org\/10.1111\/cen.14913.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2124_CR119","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1530\/EC-20-0423","volume":"9","author":"LS Silva-Bermudez","year":"2020","unstructured":"Silva-Bermudez LS, Toloza FJK, Perez-Matos MC, de Souza RJ, Banfield L, Vargas-Villanueva A, et al. Effects of oral contraceptives on metabolic parameters in adult premenopausal women: a meta-analysis. Endocr Connect. 2020;9:978\u201398. https:\/\/doi.org\/10.1530\/EC-20-0423.","journal-title":"Endocr Connect"},{"key":"2124_CR120","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1007\/s00404-024-07637-5","volume":"310","author":"SF De Medeiros","year":"2024","unstructured":"De Medeiros SF, Junior JMS, De Medeiros MAS, Yamamoto AKLW, De Medeiros CLW, Da Silva Carvalho AB, et al. Combined oral contraceptive use and obesity in women with polycystic ovary syndrome. A meta-analysis of randomized clinical trials. Arch Gynecol Obstet. 2024;310:2223\u201333. https:\/\/doi.org\/10.1007\/s00404-024-07637-5.","journal-title":"Arch Gynecol Obstet"},{"key":"2124_CR121","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/cen.14013","volume":"91","author":"H Teede","year":"2019","unstructured":"Teede H, Tassone EC, Piltonen T, Malhotra J, Mol BW, Pe\u00f1a A, et al. Effect of the combined oral contraceptive pill and\/or metformin in the management of polycystic ovary syndrome: a systematic review with meta-analyses. Clin Endocrinol (Oxf). 2019;91:479\u201389. https:\/\/doi.org\/10.1111\/cen.14013.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"e817\u201336","key":"2124_CR122","doi-asserted-by":"publisher","first-page":"202401181740314","DOI":"10.1210\/clinem\/dgad465","volume":"109","author":"J Melin","year":"2024","unstructured":"Melin J, Forslund M, Alesi S, Piltonen T, Romualdi D, Spritzer PM, et al. Metformin and combined oral contraceptive pills in the management of polycystic ovary syndrome: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024;109:e817\u201336. https:\/\/doi.org\/10.1210\/clinem\/dgad465.","journal-title":"J Clin Endocrinol Metab"},{"key":"2124_CR123","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/ejendo\/lvad082","volume":"189","author":"M Forslund","year":"2023","unstructured":"Forslund M, Melin J, Alesi S, Piltonen T, Romualdi D, Tay CT, et al. Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2023;189:S1-16. https:\/\/doi.org\/10.1093\/ejendo\/lvad082. (England).","journal-title":"Eur J Endocrinol"},{"key":"2124_CR124","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s42000-020-00182-1","volume":"19","author":"E Papadakis","year":"2020","unstructured":"Papadakis E, Sarigianni M, Tziomalos K, Mavromatidis G, Panidis D. Oral contraceptives increase platelet microparticle levels in normal-weight women with polycystic ovary syndrome. Hormones (Athens). 2020;19:565\u201371. https:\/\/doi.org\/10.1007\/s42000-020-00182-1.","journal-title":"Hormones (Athens)"},{"key":"2124_CR125","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12905-023-02187-5","volume":"23","author":"SD Yousuf","year":"2023","unstructured":"Yousuf SD, Ganie MA, Urwat U, Andrabi SM, Zargar MA, Dar MA, et al. Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-\u03b1 (TNF-\u03b1), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women. BMC Womens Health. 2023;23:68. https:\/\/doi.org\/10.1186\/s12905-023-02187-5. (England;).","journal-title":"BMC Womens Health"},{"key":"2124_CR126","doi-asserted-by":"publisher","first-page":"115381","DOI":"10.1016\/j.taap.2020.115381","volume":"411","author":"KS Olaniyi","year":"2021","unstructured":"Olaniyi KS, Oniyide AA, Adeyanju OA, Ojulari LS, Omoaghe AO, Olaiya OE. Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS. Toxicol Appl Pharmacol. 2021;411:115381. https:\/\/doi.org\/10.1016\/j.taap.2020.115381.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2124_CR127","unstructured":"Johnson DB, Sonthalia S. Flutamide. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482215\/. Accessed 23 Mar 2024. Cited 2024 Mar 23."},{"key":"2124_CR128","doi-asserted-by":"publisher","first-page":"102162","DOI":"10.1016\/j.eclinm.2023.102162","volume":"63","author":"S Alesi","year":"2023","unstructured":"Alesi S, Forslund M, Melin J, Romualdi D, Pe\u00f1a A, Tay CT, et al. Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2023;63:102162. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102162.","journal-title":"EClinicalMedicine"},{"key":"2124_CR129","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/cen.15008","volume":"100","author":"TA deOliveira","year":"2024","unstructured":"deOliveira TA, Marchesan LB, Spritzer PM. Potassium levels in women with polycystic ovary syndrome using spironolactone for long-term. Clin Endocrinol (Oxf). 2024;100:278\u201383. https:\/\/doi.org\/10.1111\/cen.15008.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2124_CR130","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1208\/s12249-021-02003-z","volume":"22","author":"RI Amer","year":"2021","unstructured":"Amer RI, Yassin GE, Mohamed RA, Fayez AM. Pharmaceutical and pharmacological evaluation of the effect of nano-formulated spironolactone and progesterone on inflammation and hormonal levels for managing hirsutism experimentally induced in rats. AAPS PharmSciTech. 2021;22:204. https:\/\/doi.org\/10.1208\/s12249-021-02003-z.","journal-title":"AAPS PharmSciTech"},{"key":"2124_CR131","doi-asserted-by":"publisher","first-page":"173745","DOI":"10.1016\/j.ejphar.2020.173745","volume":"890","author":"CA Stamerra","year":"2021","unstructured":"Stamerra CA, Di Giosia P, Ferri C, Giorgini P, Reiner Z, Johnston TP, et al. Statin therapy and sex hormones. Eur J Pharmacol. 2021;890:173745. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173745.","journal-title":"Eur J Pharmacol"},{"key":"2124_CR132","doi-asserted-by":"publisher","first-page":"9554","DOI":"10.3390\/ijms21249554","volume":"21","author":"A Cignarella","year":"2020","unstructured":"Cignarella A, Mioni R, Sabbadin C, Dassie F, Parolin M, Vettor R, et al. Pharmacological approaches to controlling cardiometabolic risk in women with PCOS. Int J Mol Sci. 2020;21:9554. https:\/\/doi.org\/10.3390\/ijms21249554.","journal-title":"Int J Mol Sci"},{"key":"2124_CR133","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.3390\/ijms20225787","volume":"20","author":"A Wojciechowska","year":"2019","unstructured":"Wojciechowska A, Osowski A, J\u00f3\u017awik M, G\u00f3recki R, Rynkiewicz A, Wojtkiewicz J. Inositols\u2019 importance in the improvement of the endocrine-metabolic profile in PCOS. Int J Mol Sci. 2019;20:5787. https:\/\/doi.org\/10.3390\/ijms20225787.","journal-title":"Int J Mol Sci"},{"key":"2124_CR134","doi-asserted-by":"publisher","DOI":"10.1159\/000536163","author":"O Pustotina","year":"2024","unstructured":"Pustotina O, Myers SH, Unfer V, Rasulova I. The effects of Myo-inositol and D-chiro-inositol in a ratio 40:1 on hormonal and metabolic profile in women with PCOS classified as phenotype A by the Rotterdam Criteria and EMS-type 1 by the EGOI Criteria. Gynecol Obstet Invest. 2024. https:\/\/doi.org\/10.1159\/000536163.","journal-title":"Gynecol Obstet Invest"},{"key":"2124_CR135","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1007\/s43032-020-00369-2","volume":"28","author":"Y Mu","year":"2021","unstructured":"Mu Y, Cheng D, Yin T-L, Yang J. Vitamin D and polycystic ovary syndrome: A narrative review. Reprod Sci. 2021;28:2110\u20137. https:\/\/doi.org\/10.1007\/s43032-020-00369-2.","journal-title":"Reprod Sci"},{"key":"2124_CR136","doi-asserted-by":"publisher","unstructured":"A M, R H, H F, F H, V K, A J, et al. Vitamin D and polycystic ovary syndrome (PCOS): a review. Annals of medicine and surgery (2012). Ann Med Surg (Lond); 2023;85. https:\/\/doi.org\/10.1097\/MS9.0000000000000879.Cited 2024 Mar 24.","DOI":"10.1097\/MS9.0000000000000879."},{"key":"2124_CR137","doi-asserted-by":"publisher","first-page":"e21237","DOI":"10.1016\/j.heliyon.2023.e21237","volume":"9","author":"M Basheer","year":"2023","unstructured":"Basheer M, Bhat AH, Ahmad Hajam Y, Batiha GE-S, Ataya FS, Fouad D, et al. Melatonin as a promising therapeutic intervention for restoring ovarian function in letrozole-induced polycystic ovary syndrome rats. Heliyon. 2023;9:e21237. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21237.","journal-title":"Heliyon"},{"key":"2124_CR138","doi-asserted-by":"publisher","first-page":"954186","DOI":"10.3389\/fcell.2022.954186","volume":"10","author":"W Chu","year":"2022","unstructured":"Chu W, Li S, Geng X, Wang D, Zhai J, Lu G, et al. Long-term environmental exposure of darkness induces hyperandrogenism in PCOS via melatonin receptor 1A and aromatase reduction. Front Cell Dev Biol. 2022;10:954186. https:\/\/doi.org\/10.3389\/fcell.2022.954186.","journal-title":"Front Cell Dev Biol"},{"key":"2124_CR139","doi-asserted-by":"publisher","first-page":"e3217","DOI":"10.1210\/clinem\/dgac294","volume":"107","author":"L Hu","year":"2022","unstructured":"Hu L, Ma L, Xia X, Ying T, Zhou M, Zou S, et al. Efficacy of bariatric surgery in the treatment of women with obesity and polycystic ovary syndrome. J Clin Endocrinol Metab United States. 2022;107:e3217\u201329. https:\/\/doi.org\/10.1210\/clinem\/dgac294.","journal-title":"J Clin Endocrinol Metab. United States"},{"key":"2124_CR140","doi-asserted-by":"publisher","first-page":"848947","DOI":"10.3389\/fendo.2022.848947","volume":"13","author":"W Yue","year":"2022","unstructured":"Yue W, Huang X, Zhang W, Li S, Liu X, Zhao Y, et al. Metabolic surgery on patients with polycystic ovary syndrome: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:848947. https:\/\/doi.org\/10.3389\/fendo.2022.848947.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2124_CR141","doi-asserted-by":"publisher","unstructured":"Ramzan H, Bukhari DA, Bibi Z, Arifullah null, Isha null, Nawaz A, et al. Probiotic supplement for the treatment of polycystic ovarian syndrome. Pharmacol Ther. 2025;266:108785. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108785","DOI":"10.1016\/j.pharmthera.2024.108785"},{"key":"2124_CR142","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12967-025-06315-7","volume":"23","author":"H Senthilkumar","year":"2025","unstructured":"Senthilkumar H, Arumugam M. Gut microbiota: a hidden player in polycystic ovary syndrome. J Transl Med. 2025;23:443. https:\/\/doi.org\/10.1186\/s12967-025-06315-7.","journal-title":"J Transl Med"},{"key":"2124_CR143","doi-asserted-by":"publisher","first-page":"2085961","DOI":"10.1080\/19490976.2022.2085961","volume":"14","author":"V Rodriguez Paris","year":"2022","unstructured":"Rodriguez Paris V, Wong XYD, Solon-Biet SM, Edwards MC, Aflatounian A, Gilchrist RB, et al. The interplay between PCOS pathology and diet on gut microbiota in a mouse model. Gut Microbes. 2022;14:2085961. https:\/\/doi.org\/10.1080\/19490976.2022.2085961.","journal-title":"Gut Microbes"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02124-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02124-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:45:55Z","timestamp":1786077955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-02124-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":143,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2124"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02124-8","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"252"}}